Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management by Heidi Cate et al.
Cate et al. BMC Ophthalmology 2012, 12:57
http://www.biomedcentral.com/1471-2415/12/57STUDY PROTOCOL Open AccessProtocol for a randomised controlled trial to
estimate the effects and costs of a patient
centred educational intervention in glaucoma
management
Heidi Cate1,2*, Debi Bhattacharya2, Allan Clark3, Richard Fordham3, Caitlin Notley3 and David C Broadway1Abstract
Background: Poor glaucoma education is thought to be a causative factor of non-adherence to glaucoma therapy.
However, the multi-factorial nature of non-adherent behaviour may explain the failure of purely educational
interventions to achieve significant improvement in adherence. Behaviour Change Counselling (BCC) allows both
the imparting of information and assessment of patient ambivalence to medication use and may elicit behaviour
change in order to achieve better adherence. The chronic and complex nature of glaucoma means that patient
non-adherence to glaucoma therapy does not easily correlate with measureable objective clinical endpoints.
However, electronic medication monitoring offers an objective method of measuring adherence without reliance
on clinical endpoints.
Methods/design: The study is a randomised controlled trial (RCT) with glaucoma (open angle) or ocular
hypertension patients attending a glaucoma clinic and prescribed travoprost. The study will determine whether
additional glaucoma education using BCC is beneficial and cost effective in improving adherence with glaucoma
therapy. An 8-month follow-up period, using an electronic adherence monitoring device (TravalertW dosing aid,
TDA), will indicate if the intervention is likely to be sustained in the longer term. Additionally, a cost-effectiveness
framework will be used to estimate the cost benefit of improving adherence. The development of a novel
intervention to deliver glaucoma education using BCC required practitioner training and fidelity testing. Five
practitioners were successfully trained to become Glaucoma Support Assistants able to deliver the BCC intervention.
The research group had prior clinical and investigative experience in this setting, and used multiple strategies to
design a method to address the study objectives.
Discussion: This RCT, using BCC to improve adherence to ocular hypotensive therapy, to our knowledge is the first
within this disease area. Using a variety of adherence measures allows examination of the known inaccuracies of
patient self-report with respect to glaucoma medication. The novel BCC component has undergone fidelity testing
using BECCI and the BCC template will ensure conformity to a standardised intervention.
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Untreated glaucoma is a chronic, progressive condition
leading to visual field loss and risk of blindness. The ma-
jority of glaucoma damage is preventable with appropri-
ate therapy [1-3] and the mainstay of treatment is eye
drops to reduce intraocular pressure (IOP) [4]. Non-
adherence to therapeutic regimens is associated with a
reduction in treatment benefit [5] resulting in additional
health service costs through changes to prescribed medi-
cation requiring additional follow-up of efficacy, wastage
of unfinished pharmaceutical supplies, or the costs of
surgery that may have been avoidable [6]. If surgical
treatment is required, there is also the increased risk of
associated adverse effects.
Patient non-adherence with anti-glaucoma therapy is
poorly understood with reported rates between 5% and
80% [7]. Historically, non-adherence has been cate-
gorised as intentional or unintentional, but the ultimate
behaviour is often an amalgam of these factors [8]. Unin-
tentional non-adherence is a passive process that pre-
vents use of medication as intended by the prescriber,
such as forgetfulness, poor comprehension of dosing
regimen or physical inability to self-administer medica-
tion. Intentional non-adherence is a deliberate decision
by the patient to deviate from the prescribed recommen-
dations by not taking medication, reducing the dosing
frequency or premature discontinuation.
According to UK national guidance [4], a typical care
pathway involves referral to a specialist glaucoma clinic
for diagnosis by standard glaucoma examination, fol-
lowed by long-term monitoring, with treatment if indi-
cated, according to risk of disease progression. Provision
of information for patients, carers and family members
is usually offered by the diagnosing clinician.
Poor glaucoma education has been cited as an ex-
planation for non-adherence to therapy [9-17] however,
the magnitude and nature of any association is not con-
sistent. A semi-structured educational session reported
by Sheppard et al. [9] identified an improvement in
participant knowledge but no significant difference in
adherence between intervention and control groups.
Sheppard’s findings may, in part, be attributable to the
small sample size (n = 73), short follow-up (12 weeks)
and failure to ascertain the fidelity of intervention de-
livery by nurses.
Studies related to oral anti-hypertensives have found
that education alone is ineffective in improving adher-
ence [18,19] and similar outcomes have been reported
with glaucoma. Three studies using education alongside
an individualised care planning programme have demon-
strated an improvement in adherence [11,16,17].
A study of a 30 minute education and tailoring program
(n=73) reported by Norell et al. [11], detected a positive,
significant improvement in adherence. Norell’s educationalcomponent was similar to other reported studies, however,
the additional ‘one to one’ tailoring program allowed the
patient to consider and discuss strategies for incorporating
the medication administration into daily activities; the
study findings were limited by a short follow-up (20 days),
no estimate of sustainability of intervention effect and no
estimate of intervention cost.
One method to overcome the issue of assuring fidelity
is to use standardised information. A web-based glau-
coma education and support intervention study [20],
used links to information on the internet for participants
to access independently. Whilst information provision
was standardised, participants controlled how much and
what information they chose to access based upon per-
sonal requirements. The study failed to significantly im-
prove adherence [20] which may partly be attributable
to the absence of direct contact with healthcare team
members, as non-adherent participants are more likely
to feel that insufficient time is devoted to them by their
healthcare team [21].
It appears that the influence of both intentional and
unintentional factors and complexities of non-adherent
behaviour may explain the failure of purely educational
interventions to achieve significant adherence improve-
ment. A Cochrane review of adherence interventions
[22] concluded that effective adherence interventions
were complex in nature which may explain the success
of the Norell et al. education and tailoring program
[11,22] relative to simple educational interventions. The
Norell et al. approach of using glaucoma assistants ra-
ther than written or IT based techniques is also sup-
ported by research which has demonstrated that
interventions using personal contact are more effective
[23]. It seems appropriate, therefore, to conduct a larger
scale trial adopting a similar approach to Norell et al.
with longer follow-up, and detailed reporting of research
methodology to demonstrate research rigour.
A further appropriate enhancement for future inter-
ventions would involve considering all factors known to
affect adherence. The Theory of Planned Behaviour sug-
gests that the best predictor of behaviour is intention
which is determined by the attitude towards the behav-
iour formed from beliefs about the likely outcomes of
behaviour and the value of that outcome [24]. Similarly,
Social Cognitive Theory considers the key constructs of
a particular behaviour to be patient belief in their cap-
ability to perform the required behaviour (self-efficacy)
and their perception that the behaviour will have a posi-
tive effect on the health condition (outcome expectation)
[25]. When patients express ambivalence to adhering to
their prescribed regimen, Motivational Interviewing (MI)
and more recently Behaviour Change Counselling (BCC)
have been developed in order to identify ambivalence
and guide patients in adopting behavioural change [26].
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enhancing intrinsic motivation to change by exploring
and resolving ambivalence’ and has been successfully ap-
plied to improving medication adherence [27-30]. MI in
its original format consisted of multiple sessions, each of
30–60 minutes. However, in a medical setting, patient
encounters usually range from 10–15 minutes and
patients often do not see the same clinician throughout
follow-up, limiting the use of MI. Additionally, in med-
ical and public health settings, there is often a multi-
component approach to care such as the provision of
educational materials and information communication
[27]. Thus, Behaviour Change Counselling (BCC), an
adaption of MI suitable for brief consultations, was
developed for use in healthcare. Whereas MI uses open
questions and reflective listening [31], BCC can add-
itionally be used to exchange information. BCC can be
of brief duration or extended to a longer time if
required, typically 5–30 minutes [32].
There are a multitude of adaptations to the original
form of MI used in randomised controlled trials (RCTs).
However, RCTs rarely report precise intervention details
and there is often no evidence of any skill assessment of
the practitioners delivering the intervention or measures
of patient-centeredness [33]. A number of instruments
measure patient-centeredness [34] but these are not
specific to health behaviour change techniques. The Mo-
tivational Interviewing Skill Code (MISC) [35] and Behav-
ioural Change Counselling Index (BECCI) [33] are specific
measures of fidelity to MI and BCC respectively. MISC ap-
plies three phases of analysis by means of direct observa-
tion of a recorded clinical encounter. MISC scores from
each phase are computed to produce an overall summary
score which can be compared to the benchmarks depict-
ing proficiency in MI techniques [35]. Despite revision in
2008 to a more streamlined process [36], MISC still
includes a number of subsections that are not essential for
users of BCC [33].
BECCI was developed to evaluate practitioner compe-
tence in using BCC in controlled trials. BECCI focuses
on the practitioner consulting behaviour, rather than pa-
tient response, in a single-phase analysis using Likert-
type scales to indicate either frequency or strength of
practitioner behaviour over 11 items to produce an over-
all mean score [33].
There are numerous approaches to measuring ad-
herence, each with merits. Patient self-report, using
questionnaires, diaries and/or interviews are cheap and
easy to administer but in comparison with objective
measures, can yield higher adherence estimates [37].
This discrepancy is attributed to both the social desir-
ability to be adherent resulting in reporting bias and
memory bias. Prescription refill databases can provide
adherence estimates based on how many prescriptionshave been ordered over a period of time, which may
show intention to use medication, but does not ensure
administration [38].
In diseases where medication adherence correlates
with therapeutic outcome, objective observations are
possible. However, with glaucoma, adherence does not
easily correlate with immediate clinical benefit and
ideally both adherence and clinical endpoints should be
assessed [39]. The chronic nature of glaucoma means
that determination of the relationship between adher-
ence magnitude and therapeutic efficacy requires long
term follow-up with assessment of optic nerve damage
and/or visual field loss. IOP may provide an alternative
measure, however, there is considerable diurnal variation
[40-42] and so there is no universal standard for using
IOP as an adherence measure [43].
An 80% adherence rate is widely recognised as ‘accept-
able’ for many systemic medications [44] but there is no
such acceptance for ocular hypotensives. However, a re-
cent cross-sectional glaucoma study in the USA found
that participants with adherence rates < 80%, according
to a medication event monitoring system (MEMSW), had
worse visual field defects than those with adherence
rates ≥ 80% [45].
Electronic drug monitoring is a more objective method
to measure adherence and particularly appropriate with eye
drops as ‘pill counting’ methods cannot be employed. Elec-
tronic monitors are, however, often expensive and cumber-
some, limiting their use. The AlconW Travatan dosing aid
(TDA; TravalertW, Alcon, Fort Worth, TX) is designed for
patients to easily reload their eye drop bottle into the device
and electronically records every drop discharged [46].
Whilst electronic monitoring devices have previously been
criticised for modifying adherence and/or behaviour by
emphasising the monitoring itself (the Hawthorne effect)
[47], a pilot study has established that the TDA had no such
demonstrable impact [48].
Methods/design
The purpose of this study was to determine whether
additional education and advice about glaucoma using a
BCC intervention, improves adherence with topical anti-
glaucomatous therapy. The objectives were to:
 Determine the effect of the intervention on
adherence.
 Determine the longevity of any intervention effect
on adherence.
 Estimate the incremental cost-effectiveness ratio
(ICER) of improving adherence.
 Describe user experiences of the educational
intervention and self perception of adherence in order
to gain a better understanding of the components of
the intervention that might improve adherence.
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social, demographic, medical and family history
information.
Intervention development
The intervention was standardised by the development
of a BCC template (Figure 1) which was informed by the
following:
 the Glaucoma Medication Adherence Model which
was derived from a qualitative study exploring
patient perceived barriers to adherence with
glaucoma medication (Figure 2) [13];
 glaucoma and ocular hypertension education
requirements identified from the literature and
expert clinician advice;
 the Satisfaction with Information about Medicines
Scale (SIMS) which has been demonstrated to be a
reliable predictor of adherence [49]. SIMS was usedA) Agenda and time setting
B) Establish patient’s initial thoughts 
medication
C) Establish patient’s baseline knowle
needs – confirm type of glaucoma 
D) Agree agenda incorporating patien
information outlined in discussion 




What creates the pressure?
How will this affect me?  
Treatment with eye drops
Drop Application Techniques
E) Establish patient’s thoughts / attitu
medication. Tailor further informati
Side effects
F) Determine patient’s optimism for tr
ambivalence
G) Discuss patient’s self efficacy and 
Tailor further information and discu
Drop taking regimen
H) Discuss patient’s outcome expecta
return to decisional balance and th
Figure 1 Behavioural change counselling template.to ensure that the BCC template contained the
standard information deemed necessary for new
glaucoma patients to make an informed decision
about use of their ocular hypertensive treatment
(travoprost).
Glaucoma support assistant training
Five Glaucoma Support Assistant (GSAs) roles were cre-
ated for the purpose of this study. Prior to recruitment,
the GSAs had worked in varying roles within the eye de-
partment (glaucoma research technician, ophthalmic
nurse, glaucoma nurse specialist (2) and glaucoma re-
search co-ordinator), all with experience of working with
glaucoma patients. Five GSAs were utilised to ensure the
results of the study were attributable to the intervention
method rather than the specific context of any one indi-
vidual delivering the intervention. The GSAs partici-
pated in BCC training and quality assurance sessions.
Training session one (4 hours duration), included a two/ attitude towards the prescribed 
dge and therefore information 
t needs; address all of the 
topics below but tailored to 
 at stage C.
de towards the prescribed 
on and discuss:  
eatment and address any  
develop strategies to enhance self
ss: 
ncy, if ambivalence identified, 
en key question.
Initial Education
1. Drop application techniques
2. Consequences of not taking drops





1. Day to day routine problems – Location, time 
restraints, storage, remembering when busy
2. Making drops last / re-ordering
3. Bottles/packaging
ADHERENCE





regimes e.g. more 













Older participants (60 and over)
Application of drops and 
remembering drops – effects of aging 
and conditions associated with older 
age make adherence more difficult e.g. 
Parkinson’s, Arthritis
Education – Some older participants 
had problems with access to self 
education (particularly using internet 
resources)
Younger participants (60 and under)
Anxiety increased due to longer life 
expectancy 
Treated differently by Eye Clinic Staff –
either more/less attentive 
Face different issues because they are at 
a different stage in life, are still working as 
opposed to retired and therefore desire to 
meet other patients in “young exclusive” 
support groups
Age Differences
Initial Education & Long term feedback –
level of satisfaction, level of information wanted 
and delivery of interventions
Correct Application – degree of initial 
problems, ongoing application problems
Remembering – frequency of forgetting, 
feelings about forgetting, cues used other than 
routine
Practical problems – Evident across all 
identified areas according to individual lifestyle
Individual Differences
Long Term Feedback and 
Education 








Figure 2 The glaucoma medication adherence model.
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predictors of behaviour. For the remainder of the ses-
sion, the GSAs were introduced to MI theory and parti-
cipated in role-play sessions facilitated by a qualified MI
coach who provided appropriate feedback. A two month
interval was then allowed to enable the GSAs to practice
the MI and BCC skills within their usual clinical duties.
At training session two (three hours duration), the GSAs
reported any problems encountered with training sessionTable 1 BECCI scoring of role play assessment
BECCI criterion GSA 1 GSA 2 GSA 3 GSA 4 GSA 5
Domain 1. Agenda setting and permission seeking
1. The practitioner invites
the patient to talk about
behaviour change
1.5 2.0 2.0 2.1 1.7
2. The practitioner
demonstrates sensitivity
to talking about other
issues
2.3 2.0 2.7 3.0 2.0
Domain 2. The why and how of change in behaviour
3. Practitioner encourages
patient to talk about current
behaviour or status quo
2.3 2.3 2.7 2.7 3.0
4. Practitioner encourages
patient to talk about
behaviour change
2.0 2.0 2.3 2.7 2.7
5. Practitioner asks questions
to elicit how patient thinks
and feels about the topic
2.0 2.3 3.0 3.0 3.0
6. Practitioner uses empathic
listening statements when
patient talks about the topic
2.0 3.0 2.7 3.0 2.7
7. Practitioner uses summaries
to bring together what the
patient says about the topic
2.3 1.0 0.7 2.3 2.0
Domain 3. The whole consultation
8. Practitioner acknowledges
challenges about behaviour
change that the patient
faces
1.3 2.3 2.7 2.0 1.7
9. When practitioner
provides information,
it is sensitive to patient
concerns and
understanding
2.7 2.7 3.0 3.0 2.3
10. Practitioner actively
conveys respect for patient
choice about behaviour
change
1.3 2.3 2.3 1.7 1.7
Domain 4. Talk about targets
11. Practitioner and patient
exchange ideas about how
the patient could change
current behaviour




2.1 2.2 2.4 2.6 2.3one after implementation. Individualised guidance was
provided in response to any reported problems and the
remaining time devoted to role-playing observed by the
MI coach, with feedback provided.
The GSAs also underwent a training session with the
Glaucoma Specialist Consultant to ensure competency
in the knowledge and skills required to deliver education
to patients about glaucoma and related issues. The GSAs
had the freedom to conduct the counselling session in
their own BCC style. Education was tailored to individ-
ual patients, but followed the BCC template (Figure 1).
Fidelity testing
Six months after training completion, GSA information
provision was assessed in terms of adherence to the
BCC template and consultation style assessed using
BECCI [33] via a video recorded session with an actor-
patient (see Table 1 for criteria). A ‘brief ’ was prepared
for the role-playing actor by the Glaucoma Specialist
Consultant and MI coach. The overview of the character
to be played by the actor-patient provided the GSAs
with an opportunity to identify ambivalence to adher-
ence arising from the non-curative nature of the treat-
ment and lifestyle barriers.
The video recorded role-play sessions were independ-
ently reviewed according to the BECCI criteria by the
MI coach and two experts in MI independent to the re-
search study. Table 1 summarises the BECCI scores by
the three assessors. The mean average BECCI score
reveals that the GSAs used behaviour change counselling
(BCC) to some extent during the simulated session;
GSA consultation compliance was 100% for 11 of the 16
BCC criteria. Three GSAs did not clearly discuss with
the patient the fact that there was no tangible effect
from using the eye drops. Two GSAs did not discuss the
patient’s expectations of adherence to treatment and for
each of the following criteria, one GSA did not clearly
address the issue during the role-play: eye drop applica-
tion technique, patient’s thoughts/attitudes regarding the
prescribed medication, patient’s optimism and perceived
self-efficacy regarding adherence to the prescribed travo-
prost. Individualised, written feedback was provided to
each of the GSAs.
GSA experiences of training and videoed
actor-patient session
Glaucoma Support Assistants were invited to participate in
a focus group. The aim of the focus group was to gain an
understanding of GSAs experiences of the preparation and
training prior to undertaking the study. The focus group
lasting one hour was audio recorded and conducted by a
moderator and assistant independent to the research study.
The recording was transcribed verbatim and the data ana-
lysed using ‘Framework’ analysis [50,51].
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that did not participate, one was the study facilitator and
part of the management team and thus not invited in
order to reduce bias, and the other member consented
but was absent due to illness.
Of all the training given to the GSAs, the ‘acting ses-
sion’ was discussed the most during the interview; this is
understandable given the GSAs described it as “a terrify-
ing experience”, and felt “really tense” prior to filming.
For this reason, the fidelity test was far from a ‘normal’
case scenario and may not be a true representation of
the interaction between participants and the GSA in the
study setting. Using an actress in a simulated setting
prohibited the fidelity test measuring true patient-
practitioner behaviour in a naturalistic setting; this could
be the reason why good information provision was evi-
dent during the role-play, but less emphasis placed on
establishing ambivalence to eye drop use and the pos-
sible effects, as the GSAs did not feel they were addres-
sing a ‘real patient’.
Study design
The study was a randomised controlled trial. A flow-
chart of the study design is shown in Figure 3. The study
received ethical approval from the Norfolk Research Eth-
ics Committee, UK.
Setting, recruitment and treatment allocation
The study was conducted in the Glaucoma Clinic at the
Norfolk and Norwich University Hospital, UK. Patients
newly diagnosed, or previously untreated, with either
glaucoma or ocular hypertension requiring the standard
first line treatment of monotherapy with travoprost,
(using established standard criteria as documented in
the European Glaucoma Society Guidelines) [52], were
invited to participate. Patients were >18 years of age,
able to give informed consent, and had adequate ability
to read and understand English. Patients requiring care-
home staff or home-help (not provided by a co-habiting
partner or family member) to apply eye drops were
excluded.
Eligible patients were randomised using an automated
telephone randomisation system to ensure allocation
concealment. Randomisation was stratified by diagnosis
(either glaucoma, or ocular hypertension/glaucoma sus-
pect) and experience of the glaucoma service (new pa-
tient or follow-up patient but first intention to treat).
Stratification controlled for possible variances, since
previous studies have shown that patients with sus-
pected glaucoma or ocular hypertension without the
presence of manifest glaucomatous disease are less ad-
herent than those with evidence of manifest glaucoma
[53,54]. Also, patients previously reviewed as out-
patients but not started on ocular hypotensivetreatment, had an increased opportunity to ask ques-
tions or self-educate before therapy initiation and be-
coming eligible to participate in the study. Patients
declining study participation, following consent, had
demographic information collected (age, gender and
index of multiple deprivation [IMD]).
Once randomised, participants were followed through
to completion of the study regardless of whether travo-
prost treatment was continued or other additions/
changes to the therapy were made.
Control group
Standard care was provided which involved attendance
to a specialist glaucoma clinic for treatment initiation.
Initiation included undergoing appropriate tests and a
consultation of approximately 10 minutes with a special-
ist glaucoma clinician. The consultation consisted of the
following:
 A brief explanation about glaucoma or ocular
hypertension
 A summary of the proposed future management
 Guidance regarding drop administration
 The relevance of glaucoma with respect to driving
and future vision.
A patient information leaflet providing information
about glaucoma in general was provided.
The intervention group
In addition to standard care, the intervention group
received the BCC intervention following the 10 minute
consultation. A telephone advice-line for patients and
their carers to respond to glaucoma related queries was
also provided by GSAs.
Outcome and data collection strategies
A summary of the data collection process is provided in
Table 2.
Primary outcome measure
Adherence magnitude: Participant adherence to travo-
prost, was measured using the TDA. Participants were
provided with written operating instructions [48] and
shown how to use the TDA, including how to replace an
empty bottle with subsequent supplies. Participants were
asked to use the TDA to administer their travoprost eye
drops for the study duration. The primary outcome
measure was the average number of doses administered
over the monitoring period, recorded by the TDA, and
percentage adherence calculated using the adjusted ad-
herence calculator [48] (calculation as in Figure 4). Ad-
herence was calculated for the total study duration and
for 8 separate monthly periods to explore trends
Standard Care Appointment with Clinician:








BCC Intervention by GSA
Standard Care Follow-up Appointment
Additional Education Available
TDA Data Collected
Visit 2 and Education & Support 
Evaluation Questionnaire Issued 
Standard Care Follow-up Appointment
TDA Data Collected
Final Questionnaire Issued
Return to Usual Care
Return to Usual Care
Control Group
Baseline Questionnaire Issued
Standard Care Follow-up Appointment
TDA Data Collected
Visit 2 Questionnaire Issued
Standard Care Follow-up Appointment
TDA Data Collected
Final Questionnaire Issued





















Figure 3 Illustration of the participant study pathway.
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tion of adherence score was used (‘adherent’ if the
average number of TDA recorded doses is ≥ 80% of
expected and ‘non-adherent’ if < 80%).
Secondary outcomes
Patterns of adherence behaviour: The TDA data were
also used to produce graphical representations of adher-
ence in order to classify patterns of adherence behaviour.The methodology and categories described by Ajit et al.
in a 3 month study [55] and data on file, were used to
classify 5 patterns of adherence; (i) discontinuation of
dosing after a short time interval, (ii) adherence ≥ 97%,
(iii) adherence < 97% ≥ 80%, (iv) frequent drug holidays,
and (v) variable with frequent missed doses.
Medication Possession Ratio (MPR): Upon study comple-
tion, computer-generated repeat prescription information
was collected from participants’ General Practitioner
Table 2 Data collection process
Method Data collected
Baseline patient visit to Glaucoma Clinic
Structured interview Medical history and social demographics
(including: age, gender, IMD, education,




Satisfaction with Information about
Medicines
Resources log Time spent with GSA (in minutes)




Satisfaction with Information about
Medicines
Morisky Medication Adherence Score
Frequency of Missed Dose Score
Possible predictors of adherence. e.g. do
you apply your own drops or does
somebody help you?
GSA Evaluation Questionnaire
(for intervention group only
and completed at home)
Satisfaction with Education and
Support from GSAs
Resources log Time spent with GSA (in minutes)
Time spent with Clinician (in minutes)
Medical notes Intraocular pressure measurement
Visit 3
Visit 3 Questionnaire Satisfaction with Information about
Medicines
Morisky Medication Adherence Score
Frequency of Missed Dose Score
Possible predictors of adherence. e.g.
do you apply your own drops or does
somebody help you?
Resources log Time spent with GSA (in minutes)
Time spent with Clinician (in minutes)
Medical notes Intraocular pressure measurement
Duration of study
Resources log Time spent with GSA on help-line
telephone calls
Evaluation of TDA data Percentage adherence score using TDA
Prescription data capture Repeat prescription count
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cate over- or under-usage of eye drop refills during the
study; MPRa [38] used the average travoprost drop count
[56] and MPRb, used the UK general prescribing instruc-
tion to renew eye drop prescriptions every 28 days
(Figure 4).
Self-reported adherence: Two self-report adherence
measures were utilised, (i) the Morisky Measure of Ad-
herence Score (MMAS) [57] which is a four-item vali-
dated measure and (ii) the Frequency of Missed Dose
(FMD) which is a measure developed by the authors toquantify the number of eye drop doses missed (once a
day, once a week, once a month, or never).
Satisfaction with information received: The validated
SIMS was used to quantify satisfaction with information
received about travoprost [49].
Patient IOP: Routinely measured and recorded IOP
results using Goldmann applanation tonometry were
obtained for each eye, at each visit, from the partici-
pants’ medical records. The IOP measurement for each
treated eye was used to calculate the % reduction in IOP
from baseline, visit 2 and 3.
Predictors of adherence
Information about baseline socio-demographic charac-
teristics and the following possible predictors of adher-
ence were collected using a structured interview; a
positive family (parent, sibling or offspring) history of
glaucoma, previous use of eye drops, use of other pre-
scribed medication and if this was used at the same time
as travoprost, and self-administration of drops or help
given by a family member. Co-morbidity was classified
using the Charlson Co-morbidity Index [58] from infor-
mation available in participant medical records.
Health economic measures
The health economic analysis was based upon the NHS
perspective of using public funds in order to deliver free
healthcare at the point of access. The primary outcome
measure was incremental hospital cost per percentage
gain in adherence. The specific costs associated with sec-
ondary care ophthalmic activity were identified on re-
view of the patient pathway by an expert clinician
(DCB), glaucoma health care professional (HC), and
health economic advisor (RF). These costs were captured
in resource logs and included; The time GSAs spent
with each participant to deliver the BCC intervention
and support the telephone helpline; on-costs were
included in the hourly calculation of cost for each GSA
according to the UK pay scale for NHS employees [59].
The cost of training GSAs in BCC were added assuming
such training is renewed triennially due to staff turnover
or updating skills and knowledge.
1. Clinician costs; calculated using the Unit Costs of
Health and Social Care methodology [60]. The cost
elements included were basic salary, salary on-costs
and on-going training. An hourly clinician-cost,
weighted by percentage of time spent in clinical
practice was calculated and applied to the time spent
with clinician as recorded in the resources log. Local
service overhead costs were also factored in. Time
spent with clinician rather than the local unit service
cost was chosen to reflect the potential difference in
consultation time between the two treatment arms.
  
 
* Adherent dose = >one recorded application during the expected dosing time # 
# Expected dosing time = calculated mean average dosing time for duration of study +/- 2 hours 
(occuring between 17:00 and 04:59 hours) 
 
# Mean no. of days/2.5 ml size bottle (ou dosing)= 51.5 (Fiscilla et al. 2003)  
*Observation period: days from index prescription until end of study, or change of treatment 
 
*Observation period: days from index prescription until end of study (change of treatment inclusive) 
Figure 4 Calculations used for outcome measures; Adherence % and Medication Possession Ratios (a and b).
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specialist nurses were recorded in the resource log
and costed using the relevant standard local unit
cost.
2. Consultation room servicing costs.
3. Additional glaucoma related standard care
procedures; included in the cost analysis if in the
opinion of two independent reviewers (HC and
DCB), they were directly related to glaucoma
management.
4. Prescription refill costs; British National Formulary
costings for 2010 [61] were used.
Costs related solely to the study were not included,
but a log maintained of the items necessary to conduct
the study (available from corresponding author). The re-
source log was utilised to calculate the intervention cost
for each participant.
A cost effectiveness analysis was undertaken to report
the additional cost of delivering a BCC intervention in
relation to the potential benefits of increased medication
adherence. The analysis included costs from the point of
randomisation to completion for each participant (pre-
randomisation ophthalmic care and initial consultation
costs were not included into the cost analysis).
Rationale for sample size calculations
The absence of an accepted adherence rate with once
daily glaucoma medication [7] and limited research to
indicate the likely effect of an intervention led to esti-
mates being derived from general medicine. In general
medicine, average non-adherence rates of 25% have been
reported [62] with interventions achieving an average35% adherence increase [23]. Reports of glaucoma ad-
herence studies using medication monitors, have had
shorter follow-up time and more complicated dosing
regimens than the proposed study [63,64]. Therefore,
without a comparable study, a 20% increase in adher-
ence was estimated for sample size power calculations
with adherence defined as ≥ 80% of expected doses
recorded by TDA. Assuming an adherence rate of 60%
in the control group and 80% in the intervention group,
81 people in each group provides 80% power to detect a
difference using a Chi-Squared test, at a 5% level of sig-
nificance. Based on an estimated 20% drop-out rate, a
target was set of 200 participants.Proposed analyses
Descriptive statistics will be used to characterise the
demographics of the study population. All analyses will
be based on the intention-to-treat principle. Missing
data will be imputed using a multivariate normal imput-
ation model after suitable transformations to ensure that
the variables are normally distributed. A total of 10
imputed datasets will be created, each analysed separately
and the results averaged using Rubin’s equations. The pri-
mary analysis will compare the percentage of “adherers” at
8 months post randomisation between intervention and
control using chi-squared. Additionally, the combined
month 7 and 8 post randomisation adherence score will
be analysed using a t-test to compare the intervention and
control group. A repeated measures analysis-of-variance
will be carried out (with time measured in months) to as-
sess for any difference between intervention and control
over time.
Cate et al. BMC Ophthalmology 2012, 12:57 Page 11 of 13
http://www.biomedcentral.com/1471-2415/12/57Secondary analyses will include a sensitivity analysis of
the primary analysis by adjusting for any baseline differ-
ences and for possible predictive variables (e.g. severity
of disease) using logistic regression. SIMS, MPR and
IOP change between 8 months and initial visit will be
analyzed using a t-test to compare the intervention and
control group. A reduction in IOP will be correlated
with the percentage adherence rate. A correlation be-
tween self-reported adherence and the TDA adherence
score will be carried out in each arm separately using a
Spearman’s correlation coefficient. The self-reported ad-
herence and SIMS scores will be compared both within
the control and intervention groups to assess any
changes in perceived quality of information given be-
tween the baseline, 2 month and end of study visits, as
well as between the two groups to compare any differ-
ences. No subgroup analyses are planned.
Logistic regression will be used to identify possible ad-
herence predictors. If appropriate, a multivariate model
will be constructed to identify independent predictors of
adherence.
The difference in total costs and adherence percentage
will be calculated incrementally between the interven-
tion and control group to provide the ICER of additional
adherence from the intervention. A deterministic sensi-
tivity analysis will be performed on the base case ICER
using patient variability in cost and outcome to deter-
mine the robustness of the economic analysis. If there is
a high degree of uncertainty, the analysis will be
bootstrapped.
Discussion
This article provides the description and rationale of an
RCT to investigate the use of an educational interven-
tion including BCC. The intention is to improve adher-
ence to ocular hypotensive therapy and to our knowledge
is the first in the UK within this disease area. The novel
BCC component has undergone fidelity testing using
BECCI and the BCC template to ensure conformity to a
standardised intervention.
Adherence studies can be fundamentally biased by the se-
lection of patients who attend follow-up appointments
since non-adherent patients are more likely to drop out of
follow-up care [22]. Thus, caution must be taken when ex-
trapolating the results of adherence studies. The present
study has made provision for this by recruiting at treatment
initiation and monitoring over the duration of two follow
up visits. The stratified randomisation also controlled for
possible variances in the type of patients recruited.
The use of multiple adherence measures allows exam-
ination of both intentional and unintentional non-adher-
ence, as prescription refill, FMD and TDA data provide
a quantitative estimate of non-adherence whilst the
MMAS provides some information about the reason forthe non-adherence. Correlating self-reported adherence
with the TDA helps to investigate the known inaccur-
acies of patient self-report with respect to glaucoma
medication. Using prescription refill data to calculate the
MPR should reveal participants who use more than one
drop when instilling medication, since they will require
more frequent refills and will have an MPR>1. The add-
itional MPR calculation based upon period of time
elapsed between refills will detect participants who do
not order enough medication to supply them for 28 days
as directed on the medication instruction label and will
have an MPR <1.0.
The TDA, provides an objective measure of adherence
which has previously been piloted by the research team.
Whilst three previous studies have reported that the
TDA accurately records drop administration [37,46,55],
the Norwich pilot study highlighted potential problems
in TDA operation by patients [48]. Following the pilot
study, patient approved operating instructions were
devised to avoid operational bias and ensure optimal
use of the device. Additionally, an adjusted adherence
calculator has been piloted to overcome the known
limitations of the TravalertW Software which calculates
the percentage adherence rate [48]. This adjusted ad-
herence calculator enables a graphical representation
of adherence behaviour patterns. The benefit of differ-
entiating between different patterns of non-adherence
which are not evident using global indices of adherence
have previously been demonstrated by Ajit et al. [55].
This study will use graphical representation of adherence
over an 8 month period, for the first time, to identify
where further education or support may help improve
long-term adherence to glaucoma medication.
There is little evidence to suggest that adherence inter-
ventions can consistently improve adherence to medica-
tion within the resources available in clinical settings.
Interventions are generally led by research teams which
cannot easily be translated into clinical practice [39].
However, this study will provide the economic costs
associated with the provision of an adherence interven-
tion led by specialist nurses and allied health profes-
sionals working within the local hospital and costs will
be based upon local sources to provide a more realistic
consideration of associated costs.
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